Mode
Text Size
Log in / Sign up

Antipsychotic exposure shows time-dependent associations with vocational recovery in schizophrenia cohort

Antipsychotic exposure shows time-dependent associations with vocational recovery in schizophrenia c…
Photo by Artfox Photography / Unsplash
Key Takeaway
Interpret antipsychotic associations with vocational recovery as time-dependent and observational, not causal.

This nationwide Danish register-based cohort study followed 65,630 individuals with incident schizophrenia spectrum disorders from 1998-2023, analyzing over 26.9 million person-weeks of data. The study examined antipsychotic exposure using both within-subject (time-varying) and between-subject (baseline) comparisons, with productive engagement (employment or education) as the primary outcome. The overall productive engagement rate was 48.2% across the cohort.

Results showed time-dependent associations: during the acute phase (0-2 years), antipsychotic exposure was associated with reduced engagement rates (HR 0.908); during consolidation (2-5 years), exposure was associated with reduced engagement (HR 0.946); and during maintenance (5+ years), exposure showed a small positive association (HR 1.019). The between-subject model yielded a subdistribution hazard ratio of 1.002 (95% CI 0.988-1.015), indicating no clear overall association when comparing individuals.

Safety and tolerability data were not reported. A key limitation identified was that integration of hospital pharmacy data revealed 6.1% exposure misclassification in studies relying solely on community records, potentially affecting accuracy. As an observational study, these findings represent associations rather than causal relationships, and the within-subject analysis was used to reduce time-invariant confounding. The practice relevance was not explicitly reported, but clinicians should recognize these findings as population-level averages that may obscure individual patient trajectories and phase-specific dynamics.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background. Antipsychotic medications are recommended for schizophrenia spectrum disorders, yet their long-term effects on functional recovery remain unclear, with conflicting evidence often derived from between-subject comparisons vulnerable to confounding by indication. Methods. We conducted a nationwide register-based cohort study of 65,630 individuals with incident schizophrenia spectrum disorders in Denmark (1998-2023). We modelled antipsychotic exposure against "productive engagement" (employment or education). We used two analytical approaches: (1) within-subject stratified Cox models with time-varying covariates to eliminate time-invariant confounding; and (2) Fine-Gray competing risks models with baseline exposure, accounting for mortality and emigration. Results. Over 26.9 million person-weeks, the overall productive engagement rate was 48.2%. Integration of hospital pharmacy data revealed 6.1% exposure misclassification in studies relying solely on community records. The primary within-subject analysis revealed significant temporal heterogeneity: medication use was associated with reduced engagement rates in the acute (0-2 years: HR 0.908) and consolidation phases (2-5 years: HR 0.946), but reversed to a small positive association in the maintenance phase (5+ years: HR 1.019). The between-subject Fine-Gray model, which estimates cumulative engagement probabilities, yielded an SHR of 1.002 (95% CI 0.988-1.015), a population-level average that obscured these phase-specific dynamics. Conclusions. Antipsychotic pharmacotherapy exerts a time-dependent, biphasic impact on vocational recovery. We identified a window of vulnerability during the post-acute "consolidation" phase (years 2-5) where treatment is associated with a transient reduction in productive engagement, before becoming protective after five years. These findings challenge the assumption that symptomatic stability automatically facilitates functional reintegration.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.